GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ViewRay Inc (OTCPK:VRAYQ) » Definitions » Capex-to-Operating-Cash-Flow

VRAYQ (ViewRay) Capex-to-Operating-Cash-Flow : 0.00 (As of Mar. 2023)


View and export this data going back to 2014. Start your Free Trial

What is ViewRay Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

ViewRay's Capital Expenditure for the three months ended in Mar. 2023 was $-1.18 Mil. Its Cash Flow from Operations for the three months ended in Mar. 2023 was $-53.60 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


ViewRay Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for ViewRay's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ViewRay Capex-to-Operating-Cash-Flow Chart

ViewRay Annual Data
Trend Nov13 Nov14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ViewRay Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ViewRay's Capex-to-Operating-Cash-Flow

For the Medical Devices subindustry, ViewRay's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ViewRay's Capex-to-Operating-Cash-Flow Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ViewRay's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where ViewRay's Capex-to-Operating-Cash-Flow falls into.


;
;

ViewRay Capex-to-Operating-Cash-Flow Calculation

ViewRay's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2022 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-3.898) / -91.708
=N/A

ViewRay's Capex-to-Operating-Cash-Flow for the quarter that ended in Mar. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-1.177) / -53.599
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ViewRay  (OTCPK:VRAYQ) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


ViewRay Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of ViewRay's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


ViewRay Business Description

Traded in Other Exchanges
N/A
Address
1099 18th Street, Suite 3000, Denver, CO, USA, 80202
ViewRay Inc is a radiation therapy and imaging technology company. It designs, manufactures, and markets radiation therapy systems that provide real-time imaging during radiation treatment. Its product portfolio encompasses The MRIdian linac system, The MRIdian system, the Monte Carlo treatment planning system, etc. The company holds the license for its combination of MRI and radiation therapy technologies. Geographically, it derives a majority of its revenue from the United States.
Executives
Karen Prange director 1108 S RIO VISTA BLVD, FORT LAUDERDALE FL 33316
B Kristine Johnson director 366 FERNDALE RD S, WAYZATA MN 55391
Sanket Shah officer: SVP, General Counsel C/O VIEWRAY, INC., 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH 44146
Farhad Fred Ebrahimi 10 percent owner 191 UNIVERSITY BLVD., #246, DENVER CO 80206
Caley Castelein director THOM. WEISEL HEALTHCARE VENTURES, ONE MONTGOMERY STREET, SAN FRANCISCO CA 94104
Paul Jr Ziegler officer: Chief Commercial Officer C/O VIEWRAY, INC., 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH 44146
Scott William Drake director, officer: President and CEO 9965 FEDERAL DRIVE, COLORADO SPRINGS CO 80921
Adam Andrew Podbelski officer: SVP, Customer Services C/O VIEWRAY, INC., 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH 44146
Jacob Edward Signoriello officer: Chief Financial Officer C/O VIEWRAY, INC., 1099 18TH STREET, SUITE 3000, DENVER CO 80202
James F. Dempsey director, officer: Chief Scientific Officer C/O VIEWRAY INCORPORATED, 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH 44146
Burke William P. Mr. officer: Chief Financial Officer HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Susan C Schnabel director C/O CREDIT SUISSE FIRST BOSTON, 11 MADISON AVE, NEW YORK NY 10010
Brian K Roberts director DIGITAS INC.,, 800 BOYLSTON STREET, BOSTON MA 02199
Zachary William Stassen officer: Chief Financial Officer C/O VIEWRAY, INC., 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH 44146
Daniel Jeffrey Moore director 100 CYBERONICS BVLD, HOUSTON TX 77058

ViewRay Headlines

From GuruFocus

ViewRay Inc Annual Shareholders Meeting Transcript

By GuruFocus Research 02-15-2024

Q4 2021 ViewRay Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

Preliminary Q1 2023 ViewRay Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

ViewRay Inc Clinical Data Update Call Transcript

By GuruFocus Research 02-15-2024

Q1 2019 ViewRay Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

Q2 2021 ViewRay Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

ViewRay Inc Annual Shareholders Meeting Transcript

By GuruFocus Research 02-15-2024

Q2 2020 ViewRay Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

Q1 2020 ViewRay Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024